Wednesday 20 June 2018

Sun Pharma to buy Ranbaxy in $3.2bn deal

Sun Pharmaceutical Industries said it will buy Ranbaxy Laboratories in a $3.2 billion all-share deal, creating the world's fifth-largest generic drug maker from two firms struggling with quality issues in the lucrative US market.


Ranbaxy pleads guilty, to pay $500m settlement

Indian generic drugmaker Ranbaxy Laboratories pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the US Department of Justice.


FDA says Ranbaxy plant falsified data

A plant owned by Indian generic drugmaker Ranbaxy Laboratories falsified data and test results in approved and pending drug applications, US regulators said on Wednesday. The Food and Drug Administration said it halted reviews of drug appl


Ranbaxy in Bahrain lab tieup

SRL Ranbaxy, one of India's top pathology laboratories, has joined hands with a Bahrain group to develop world-class diagnostic services in the kingdom. SRL Ranbaxy, South Asia's largest pathology laboratory network which is certified by

 1 2 3 4 5 >  Last ›

calendarCalendar of Events